Novo Nordisk (NVO) Stock Falls as Pediatric Trial Impresses but Heart Drug Trials Are Cut
TLDR
- Semaglutide helped 40.4% of children aged 6 to under 12 move below the obesity threshold after 68 weeks in the STEP Young trial
- None of the placebo group achieved the same BMI result during the trial
- Novo scrapped two additional trials of cardiovascular drug ziltivekimab after a monitoring committee found low likelihood of success
- Ziltivekimab had already failed a major late-stage cardiovascular trial in July
- NVO stock was down 1.92% on the day
Novo Nordisk delivered a mixed bag on Monday. Positive data from a pediatric obesity trial landed alongside fresh news that two more cardiovascular drug trials had been scrapped.
NVO was trading down 1.92%, at $46.60, as the market weighed up both developments.
The STEP Young phase 3 trial tested once-weekly semaglutide in 165 children aged 6 to under 12 with obesity. After 68 weeks, 40.4% of those who received semaglutide dropped below the obesity BMI threshold. None of the children in the placebo group reached that mark.
… Continue reading the full article at the original source below.
This content is automatically aggregated. Full credit goes to the original publisher (coincentral.com).
